🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

86 results for “Eye” Clear

  1. Placebo for AMG 732 will consist of site-sourced normal saline in sterile single-use vials or ampoules, AMG 732

    Amgen

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  2. Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension, Brimonidine Tartrate 0.2% w/v Eye Drops., Alphagan 2 mg/ml colirio en solución, IMGN151

    AbbVie Deutschland GmbH & Co. KG

    Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer

    phase 2 small molecule active

    1 trial

  3. Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID

    Aldeyra Therapeutics

    Dry Eye

    phase 2 small molecule completed

    1 trial

  4. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Syndrome

    phase 2 small molecule completed

    1 trial

  5. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  6. SHJ002/Vehicle

    Biotech Pharmaceutical Co.,

    Dry Eye Disease

    phase 2 small molecule completed

    1 trial

  7. Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept

    Regeneron UK Limited

    Thyroid Eye Disease

    phase 2 small molecule completed

    1 trial

  8. VEGF Trap Eye

    Regeneron UK Limited

    Macular Degeneration

    phase 2 small molecule completed

    1 trial

  9. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Dry Eye

    phase 2 small molecule active

    2 trials

  10. Verkazia 1 mg/mL eye drops, emulsion

    Laboratoire HRA Pharma

    Vernal Keratoconjunctivitis (VKC)

    phase 2 small molecule active

    1 trial

  11. Voclosporin Ophthalmic Solution

    Aurinia Pharmaceuticals

    Dry Eye

    phase 2 small molecule completed

    1 trial

  12. aflibercept injection (VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    phase 2 mab completed

    1 trial

  13. rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada

    Dompe' Farmaceutici S.p.A.

    Dry Eye

    phase 2 small molecule active

    1 trial

  14. Aceclidine + Brimonidine

    LENZ Therapeutics

    Eye Diseases

    phase 1 small molecule completed

    1 trial

  15. Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease

    H. Lundbeck A/S

    Active, moderate-to-severe TED

    phase 1 other active

    1 trial

  16. Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

    Lacuna Pharma Pty Ltd

    Glaucoma

    phase 1 other active

    1 trial

  17. VEGF Trap-Eye

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 1 small molecule completed

    1 trial

  18. ZB001 for injection

    Zenas BioPharma

    Thyroid Eye Disease

    phase 1 small molecule completed

    1 trial

  19. iNexin™ (0.08% aCT1)

    United Therapeutics Europe Ltd

    Dry Eye Disease

    phase 1 small molecule completed

    1 trial

  20. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Wet Macular Degeneration

    approved small molecule completed

    1 trial

  21. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Neovascular Macular Degeneration

    approved small molecule completed

    1 trial

  22. Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema (DME)

    approved small molecule active

    1 trial

  23. Atropine 1.0% eye drops solution

    Disc Medicine

    Myopia

    approved small molecule active

    1 trial

  24. Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources